Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure

Read full text
Authors: Rami Kahwash, Javed Butler, Muhammad Shahzeb Khan, David Zhang, Jonathan Dukes, Madhu Reddy, Rachel M. Kaplan, Anish Amin, Rahul Kanwar, Shantanu Sarkar, Verla Laager, Jennifer Wehking
+57 more Brian Van Dorn, Bart Gerritse, Nirav Patel, Aimee Laechelt, Michael R. Zile, Devi Nair, Sunit‐Preet Chaudhry, Ruple Galani, Steven Heatherly, Sumit Verma, Stephen Mester, Ambrose Panico, Jonathan Dukes, Barry Bertolet, Matthew Goldstein, Benjamin Rhee, Elie Gharib, Selma Mohammed, Hector Garcia, Gabriel Sayer, Cameron Lambert, Renee Sangrigoli, Mark Metzl, Sumant Lamba, Prasad Chalasani, Michael Cammarata, James Lyons, Amir Malik, Gregory Jackson, David Newton, Laura Gravelin, Eddie Brown, Chike Obi, Robert Sanchez, Kent Morris, John Rommel, Anupam Basuray, Patrick Gregory, James Ampadu, Deepthi Mosali, Rita Jermyn, Lynne Hung, David Zhang, Cyrus Buhari, Erich Kiehl, Ira Dauber, Hal Skopicki, John Mignone, Gian Carlo Giove, Ankit Bhatia, Frank McGrew, Raul Torres, Madhu Reddy, Robert Long, Isaac Rhea, Darius P. Sholevar, George Sokos
Cited by: 1
References: 46

Abstract

BACKGROUND: Arrhythmia burden in ambulatory patients with symptomatic heart failure (HF) without cardiac implantable electronic devices (CIEDs) is not well defined, and it remains uncertain whether device-guided remote congestion management modifies arrhythmia occurrence. OBJECTIVES: The goal was to assess whether arrhythmia burden differed between randomized congestion-management strategies and characterize the occurrences and associations of insertable cardiac monitor (ICM)-detected arrhythmias with therapeutic actions and clinical events. METHODS: In ALLEVIATE-HF, patients with NYHA functional class II-III HF with any ejection fraction (EF) and a recent HF event, without prior CIEDs, underwent ICM implantation and were randomized to ICM-guided, physician-directed, nurse-facilitated congestion management or usual care. In both arms, arrhythmia data were accessible to investigators, and arrhythmia-related management was clinician directed. Arrythmia occurrence was estimated using Kaplan-Meier methods. Associations with therapeutic interventions and clinical events were evaluated using time-varying Cox models. RESULTS: The analysis included 711 patients (mean age 70.5 ± 10.4 years; 45.7% women; mean follow-up 17.3 ± 8.9 months); 67.9% had HF with preserved EF, and 60.2% were NYHA functional class II at baseline. During the 13-month randomized phase, arrhythmia occurrence rate did not differ between the study arms. The 3-year overall occurrence of atrial fibrillation (AF) was 66.6%, with an incidence of new-onset AF of 25.4%. Bradyarrhythmia occurred in 47.1% of patients, and ventricular tachycardia or fibrillation (VT/VF) in 20.1%. ICM-recorded arrhythmia was associated with subsequent increase in arrhythmia-related interventions (HR: 3.81; VT/VF and VT/VF-related interventions, HR: 7.04; AF and AF-related interventions, HR: 3.28; bradyarrhythmia and bradyarrhythmia-related interventions, HR: 7.22; all P < 0.001). ICM-recorded arrhythmia was associated with increased risk of all-cause hospitalization (HR: 1.79; P < 0.001) and HF events (HR: 1.69; P = 0.003). Therapeutic CIED implantation and ablation occurred in 22.7% and 26.1%, respectively. Bradyarrhythmias were more common in patients with EF ≥50%, whereas VT/VF occurred more frequently in EF

Fields of Study & Subjects

Cardiac pacing and defibrillation studies Healthcare Technology and Patient Monitoring Cardiovascular Syncope and Autonomic Disorders

Publication details

Journal / source
Journal of the American College of Cardiology
Publisher
Elsevier BV
Volume
87
Issue
25
Pages
3611–3628
Publication date
27 May 2026
Language
EN